Active Ingredient History
Pazopanib (VOTRIENT) is an orally bioavailable multi-targeted tyrosine kinase receptor inhibitor. Pazopanib inhibits vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR) -1 and -3, cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In an vitro study, pazopanib exerted anti-tumor effect through mechanisms including the Raf-MAPK/ERK (MEK)-extracellular signal-regulated kinase (ERK) pathway. It has good oral exposure and inhibits angiogenesis and tumor growth in mice. Pazopanib (VOTRIENT) was developed by GlaxoSmithKline for the treatment of solid tumours and age-related macular degeneration. However, Novartis acquired all the rights to the drug from GlaxoSmithKline. Pazopanib (VOTRIENT) is indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anemia (Phase 2/Phase 3)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 4)
Breast Neoplasms, Male (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Islet Cell (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2/Phase 3)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Central Nervous System Neoplasms (Phase 2)
Cholangiocarcinoma (Phase 2)
Chondrosarcoma (Phase 2/Phase 3)
Chondrosarcoma, Mesenchymal (Phase 2/Phase 3)
Choriocarcinoma (Phase 1)
Colonic Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 1)
Corneal Neovascularization (Phase 1/Phase 2)
Dermatology (Phase 2/Phase 3)
Endometrial Neoplasms (Phase 4)
Epistaxis (Phase 2/Phase 3)
Fallopian Tube Neoplasms (Phase 2)
Fibrosarcoma (Phase 2/Phase 3)
Gallbladder Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
Genital Neoplasms, Female (Phase 1)
Germinoma (Phase 1)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 1)
Hemangioendothelioma (Phase 2)
Hemangiosarcoma (Phase 2)
Histiocytic Sarcoma (Phase 2/Phase 3)
Intestinal Neoplasms (Phase 2)
Kidney Diseases (Phase 2)
Kidney Neoplasms (Phase 2)
Leiomyosarcoma (Phase 2/Phase 3)
Leukemia, Myeloid, Acute (Phase 2)
Liposarcoma (Phase 2/Phase 3)
Liver Neoplasms (Phase 1)
Lung Neoplasms (Phase 2/Phase 3)
Lymphedema (Phase 2)
Lymphoma (Phase 1)
Macular Degeneration (Phase 2)
Melanoma (Phase 2)
Mesothelioma (Phase 2)
Multiple Endocrine Neoplasia Type 1 (Phase 2)
Nasopharyngeal Neoplasms (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms ()
Neoplasms, Germ Cell and Embryonal (Phase 2)
Nerve Sheath Neoplasms (Phase 2/Phase 3)
Neuroblastoma (Phase 1)
Neuroendocrine Tumors (Phase 2)
Neurofibrosarcoma (Phase 2/Phase 3)
Osteosarcoma (Phase 2/Phase 3)
Ovarian Neoplasms (Phase 4)
Pancreatic Neoplasms (Phase 2)
Paraganglioma (Phase 2)
Paraganglioma, Extra-Adrenal (Phase 2)
Penile Neoplasms (Phase 2)
Perivascular Epithelioid Cell Neoplasms (Phase 2/Phase 3)
Pharmacokinetics (Early Phase 1)
Pheochromocytoma (Phase 2)
Prostatic Neoplasms (Phase 2)
Psoriasis (Phase 1)
Rhabdomyosarcoma (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 4)
Sarcoma, Alveolar Soft Part (Phase 2/Phase 3)
Sarcoma, Clear Cell (Phase 2/Phase 3)
Sarcoma, Synovial (Phase 2/Phase 3)
Self Efficacy (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Solitary Fibrous Tumors (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Telangiectasia, Hereditary Hemorrhagic (Phase 2/Phase 3)
Thyroid Neoplasms (Phase 4)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Diseases (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Diseases (Phase 2)
Uterine Neoplasms (Phase 2)
von Hippel-Lindau Disease (Phase 2)
Wilms Tumor (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
